What did @thekarlatobie actually say?
She's at week 10 on Mounjaro, down 25 pounds, and two weeks into the 5mg dose. Her words: "she's doing what needs to be done." She also reported dramatically reduced appetite, saying "I be going hours without thinking about food," and paired the medication with home workouts and consistent hydration. She also flagged that injecting into the back of the arm hurt more than expected, despite other users hyping it up.
To be clear, she's not making wild medical claims here. This is a progress update, not a health advice video. She's describing her personal experience with tirzepatide (the active ingredient in Mounjaro), and she's doing it honestly, including the parts that weren't great. That context matters when evaluating what's actually worth fact-checking.
Does the science back this up?
A 25-pound loss over 10 weeks is on the higher end but not implausible, especially in the early phase of tirzepatide treatment. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found participants on tirzepatide lost up to 20.9% of body weight over 72 weeks, with the steepest losses often occurring early.
The appetite suppression she describes, going hours without thinking about food, is well-documented. Tirzepatide works on both GIP and GLP-1 receptors, a dual-agonist mechanism that appears to produce stronger appetite reduction than GLP-1-only drugs like semaglutide. A 2023 study by Frías et al. in Diabetes Care confirmed significantly reduced caloric intake and hunger scores in tirzepatide users compared to placebo. The combination of medication, movement, and hydration she describes is consistent with how these outcomes are achieved in clinical settings. The drug does not work in isolation.
What did they get wrong (or right)?
Mostly right, with some gaps worth noting. The 25-pound figure is self-reported and unverified, but that's expected for a personal update video. No one's asking her to show a DEXA scan.
Where it gets murkier: she's two weeks into 5mg, which means she likely started at 2.5mg per the standard Mounjaro titration schedule. The weight loss she's describing spans the full 10 weeks, not just the 5mg phase, so attributing results solely to "5mg gang" slightly misrepresents the timeline. The early dose phases contribute to overall outcomes too.
On injection sites, her arm pain complaint is legitimate. The posterior upper arm is an approved Mounjaro injection site, but subcutaneous fat distribution varies significantly. Leaner arms or incorrect pinch technique can result in intramuscular injection, which is more painful and may affect absorption. This is not a minor detail. A 2021 review by Usach et al. in Diabetes Therapy found injection technique errors are common and can impact both tolerability and drug delivery.
What should you actually know?
Tirzepatide is producing some of the strongest weight loss data seen in a pharmaceutical trial to date. That's not hype, that's what the phase 3 numbers show. But the outcomes vary considerably by individual, and early rapid loss does not always predict long-term trajectory. Some people plateau; others regain weight after discontinuation.
On injection sites: the abdomen, thigh, and upper arm are all approved for Mounjaro. The abdomen tends to have the most consistent subcutaneous fat layer, making it the easiest site for most people. Rotating sites is recommended to prevent lipohypertrophy, a buildup of fatty tissue that can reduce absorption over time. If the arm hurts, that is useful information, not just a complaint.
Finally, her lifestyle factors matter more than the video makes obvious. Home workouts and hydration are not just feel-good add-ons. Energy expenditure and lean mass preservation during GLP-1-assisted weight loss are active areas of concern in the research. Muscle loss during rapid weight loss is real, and resistance training helps counter it.
The bottom line
This video is a good-faith personal update, not misinformation. The weight loss she describes is within the range the clinical data supports. Her appetite suppression experience matches the mechanism of the drug. Her arm pain is a real and underreported injection site issue. The main thing she gets slightly wrong is framing 10 weeks of results as a 5mg story, when the earlier dose phases laid groundwork too. Give credit where it's due: she's staying consistent, she's not overselling the drug, and she's asking her community practical questions about technique. That's more than most.